Licensing agreement deal value for innovative T-cell receptor (TCR) immunotherapy drugs surged in 2024, with European ...

Senti Biosciences reports promising Phase I results for SENTI-202 in acute myeloid leukemia, with two of three patients ...

New results from the RESOLUTION trial demonstrate the efficacy of Vyepti (eptinezumab) on top of patient education for ...

French immunotherapy company OSE Immunotherapeutics announced that it has strengthened the company’s leadership and executive ...

Bausch Health has appointed Dr Jonathan Sadeh as executive vice president, chief medical officer and head of R&D.

Ipsen signs a global licensing deal with Biomunex for BMX-502, a novel T cell engager targeting solid tumors, potentially ...

Swedish pharma Orexo and Germany-based digital therapeutics company GAIA have decided to end their partnership agreement for ...

A Feature on M&A, licensing, and partnership tapping into AI’s potential to improve drug development.

Switzerland-based Novocure saw its shares leap 38% to $27.64 as it revealed positive results from the pivotal, Phase III ...

USA-based rare disease drug developer PTC Therapeutics has signed an exclusive global license and collaboration agreement ...

GLP-1 receptor (GLP-1R) products have gained immense popularity in recent years, and four are currently approved in major ...

Donald Trump’s potential re-election may boost biopharma mergers and acquisitions by easing regulatory scrutiny following ...